Loading clinical trials...
Loading clinical trials...
Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study With Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial
Conditions
Interventions
RVT-1601
Placebo
Locations
81
United States
University of Alabama
Birmingham, Alabama, United States
University of California Davis
Sacramento, California, United States
University California San Francisco
San Francisco, California, United States
National Jewish Health
Denver, Colorado, United States
Ascension Medical Group / St. Vincent's Lung Institute
Jacksonville, Florida, United States
University of Miami
Miami, Florida, United States
Start Date
March 29, 2019
Primary Completion Date
May 29, 2020
Completion Date
June 5, 2020
Last Updated
June 11, 2020
NCT07466420
NCT06504446
NCT05975983
NCT06634823
NCT06766175
NCT05362097
Lead Sponsor
Respivant Sciences GmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions